Articles tagged with Vaccine Development
MSU researchers aim to disrupt viral fusion, a shared mechanism between flu and HIV, to develop universal vaccines. This could lead to multi-year protection against multiple flu subtypes and effective HIV vaccines targeting multiple strains.
Scientists at the University of Osaka have developed a method to recreate human B cells with germinal center features using three immune signals, which closely match those found in human tonsils. This breakthrough could help improve vaccine-induced antibody responses and identify targets for autoimmune disease.
Scientists at Queen Mary University of London discovered a way to overcome cell's natural defences against self-amplifying mRNA vaccines, enabling the production of significantly more of their target protein. This innovation could provide longer-lasting protection at lower doses, opening new possibilities in gene therapy, cancer immuno...
Researchers at MIT have found a way to stabilize lipid nanoparticles used to deliver RNA vaccines, making them more heat-resistant. This breakthrough could allow for wider distribution and enable novel administration methods like microneedle patches.
Researchers have discovered a new vulnerability in the malaria parasite Plasmodium vivax, which can be targeted by antibodies to block liver infection and prevent relapses. The discovery provides a new target for developing a vaccine against P. vivax, the most widespread malaria parasite outside sub-Saharan Africa.
This technology rescues segmented negative-sense RNA viruses directly from complementary DNA in Vero cells, streamlining live-attenuated vaccine production. It utilizes non-cancerous Vero cells and employs triggered endosome escape transfection techniques for efficient delivery.
Researchers have developed IgA monoclonal antibodies that provide immediate immunity to dengue infection and reduce the risk of severe disease in individuals with preexisting immunity. This technology overcomes the challenge of Antibody-Dependent Enhancement, enabling effective prevention and treatment of dengue virus infection.
Researchers have developed a technology that combines aminoglycoside antibiotics with PKZ18 analogs, resulting in up to an 8-fold increase in efficacy and reduced risk of microbial resistance. This synergy enables targeting of bacteria in various environments, expanding the therapeutic window.
The symposium celebrated Dr. Lee Ho-wang's 50th anniversary of Hantaan virus discovery, reviewing its historical significance and future research directions. Key findings included the development of Hantavax, the world's first epidemic hemorrhagic fever vaccine, and strategies for infectious disease response.
Scientists at Scripps Research develop a blueprint for stabilizing key influenza proteins to create next-generation vaccine candidates. The new design strategy uses self-assembling protein nanoparticles to generate stable versions of the HA protein, which can be used to train the immune system to recognize and fight influenza viruses.
A new flu vaccine, made using baker's yeast, has shown strong immune responses in mice, protecting against three different strains of flu, including those that mutate slowly. The vaccine targets the M2 protein, which is less likely to mutate and could provide broader protection against future flu strains.
Researchers at the University of Michigan Engineering have developed a process to manufacture flu vaccines in baker's yeast, producing virus-like particles that protect mice against multiple influenza strains. The approach aims to provide long-lasting protection, possibly even a lifetime, against multiple strains and subtypes.
A new Cochrane map has identified significant gaps in dengue prevention research, with most studies lacking synthesis into reliable reviews that policymakers can use. The map highlights areas such as vaccine implementation, adult mosquito control, and environmental interventions, which require more evidence to inform effective dengue c...
Researchers developed a method to inhibit lipid nanoparticle migration into the liver by coating hepatic sinusoidal walls with polyethylene glycol. This coating reduced liver accumulation by several dozen times and increased protein expression in the spleen, promoting safer nanomedicine with lower dosages.
New research finds increasing nanoparticle binding strength promotes stronger and more durable immune responses in mice. By fine-tuning molecular structures, researchers aim to create better vaccines for long-term HIV protection.
Researchers developed an innovative vaccine strategy that uses genetically modified viruses to protect against Chikungunya and other diseases. The new approach generates antibodies without causing disease, paving the way for a robust vaccine platform with broad protective potential.
A vaccine targeting KRAS mutations was safe and stimulated durable immune responses in high-risk individuals. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some precancerous lesions shrank or stopped growing.
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. The results point to potential biomarkers that may help identify patients most likely to benefit from this approach.
Genital herpes is a viral infection that establishes a lifelong infection by entering nerve cells and can be relieved with medication. Researchers have identified glycoprotein G as a promising target for a future vaccine, which could provide protection against HSV-2 spread to the nervous system.
A new study at RMIT University has identified conditions that help protect mRNA particles in dry vaccine patches, providing practical guidance for future patch design. This research could make future mRNA vaccines easier to store and distribute, particularly in lower-resource settings where cold-chain logistics are a barrier.
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses. The vaccine resulted in the best HIV-fighting antibody response ever seen in primates, with human trials now underway.
The Vaccine Innovation Center will develop a next-generation mRNA-based hantavirus vaccine using proprietary domestic technologies, leveraging self-amplifying mRNA and lipid nanoparticle delivery systems. Preclinical studies have demonstrated strong immunogenicity and protective effects.
Researchers developed a two-part vaccination method that prevented genital herpes infection in mice, with 80% of treated mice showing no signs of disease. The 'prime and pull' approach uses nanoparticles to stimulate local immunity, establishing strong immune cell and antibody responses against the virus.
Researchers developed an mRNA vaccine that targets neuroblastoma, delaying tumour development by 10-11 days and reducing tumour size by 70% in preclinical models. The vaccine uses peptide nanoparticles to target GPC2, a protein found on the surface of neuroblastoma cells.
Researchers designed artificial proteins that simultaneously form pentagonal and hexagonal arrangements to create virus-like structures. These structures can stably carry drugs, genetic materials, and enzymes within their interior space.
A new dual vaccine against Lassa fever and rabies has been shown to be safe and induce immune responses against both viruses. The vaccine could potentially streamline delivery in settings where access is limited, reducing the need for separate vaccination efforts.
The ACT-CHIK project will conduct a Phase Ib/III clinical trial to evaluate the safety and immunogenicity of a measles-virus-based chikungunya vaccine in four African countries. The project also aims to strengthen Africa's vaccine ecosystem by transferring the vaccine manufacturing process to an African manufacturer.
A study published in JAMA Network Open found that maternal RSV vaccination reduces hospitalization risk in young infants by nearly 70%. The vaccine also showed effectiveness against severe lung infections caused by the virus.
A universal Sarbeco coronavirus vaccine has shown safety and no significant side effects in a human clinical trial, providing protection against multiple viruses, including SARS-CoV-2. The vaccine uses an AI-designed super-antigen to offer lasting protection against emerging virus threats.
The new vaccine adjuvant induces a strong mucosal immune response in the GI tract, which is crucial for eradicating polio. The researchers achieved a 20-fold increase in antibodies needed for mucosal immunity compared to the existing injectable polio vaccine.
A new leishmaniasis vaccine, developed using CRISPR gene-editing technology, is set to begin testing in healthy people for its safety and immune response. The vaccine has shown strong results in mice and has cleared a key FDA hurdle, paving the way for Phase 2 trials aiming to understand its effectiveness.
Researchers at Southwest Research Institute (SwRI) and Texas Biomedical have identified nearly two dozen antiviral compounds that could potentially treat Bundibugyo Ebolavirus. The project utilizes AI and machine learning tools to quickly identify drug candidates, with Texas Biomed set to screen the compounds in the coming weeks.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
Researchers have discovered the missing genes and enzyme that tobacco plants need to make nicotine, solving a mystery that has puzzled scientists for nearly two centuries. The discovery could lead to safer production of medicines and vaccines using tobacco plants, without the unwanted nicotine.
Researchers created a new way to boost T-cell response to mRNA vaccines, yielding more powerful anti-cancer effects and stronger protection against infectious diseases. The innovation enabled the immune system to completely eradicate most tumors in mouse models.
A phase 2 human clinical trial of a hookworm antigen has shown effective in limiting the intensity of infection, paving the way for a vaccine. The study found that vaccination with Na-GST-1 reduced the severity of infection in participants.
A new vaccine strategy has generated antibodies capable of neutralising highly divergent HIV variants in an animal model. The study provides new insights into how the immune system can be guided towards a particularly protected part of the virus, which is important for developing an effective HIV vaccine.
A nationally representative survey found that nearly 7 in 10 people trust vaccine scientists to act in their best interests, similar to medical scientists and scientists in general. The public perceives vaccine scientists as credible, self-correcting, and unbiased, with their work benefiting society.
Researchers at the University of Nebraska-Lincoln have developed a promising new vaccine approach against highly pathogenic bird flu (H5N1) that demonstrates strong efficacy in both mice and dairy cattle. The vaccine platform protects against multiple H5N1 strains and generates immunity in both the bloodstream and respiratory tract.
Researchers developed a new flu vaccine approach targeting specific but distinct regions of the influenza virus protein. This method broadened the immune response, leading to broader protection against various strains. The study's findings have implications for fighting other fast-changing viruses like COVID-19 and RSV.
Researchers have found that COVID vaccines can train immune cells to remember the SARS-CoV-2 virus and protect against severe infection for years afterward. However, the continued spread of disease has scientists taking a closer look at how the immune system builds up immune memory over time.
Researchers found that squalene-based adjuvants activate distinct pathways for vaccine protection and reactogenicity, including the role of IL-1β in enhancing efficacy and IL-1α in triggering local swelling. The study's findings could lead to safer vaccine design by targeting specific immune mechanisms.
Researchers found that obesity significantly impaired antibody production to a Pseudomonas aeruginosa vaccine in mouse models. The study suggests prioritizing tissue-resident immunity to boost protection against infections. Understanding this relationship addresses a significant gap in current vaccine research.
Researchers at Scripps Research create a nanodisc platform that preserves key parts of viral surface proteins, allowing for better understanding of antibody interactions. This approach can be applied to other viruses with similar membrane-embedded proteins, such as influenza and SARS-CoV-2.
A novel flu vaccine platform uses cell-derived extracellular vesicles to induce cross-protective immunity against influenza virus infections. The vaccine shows promise as an effective mucosal vaccine strategy.
Researchers at Karolinska Institutet have mapped immune gene variation across multiple global populations, identifying common genetic variants that affect antibody production. The findings may contribute to understanding infection susceptibility and inform vaccine design.
Researchers redesigned a key component of lipid nanoparticles to steer particles toward lymph nodes, reducing off-target delivery. This advancement could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.
The Butantan-DV dengue vaccine, developed in Brazil, shows 80.5% effectiveness against severe cases over five years, with no hospitalizations in the vaccinated group. The vaccine was 65% effective in preventing symptomatic dengue during the five-year monitoring period.
A new study discovered that a multifaceted infection prevention and control intervention successfully disrupted a large and long-running bacterial outbreak of Klebsiella pneumoniae in a Zambian neonatal intensive care unit. The study found that low-cost measures, including IPC training, enhanced cleaning, and hand hygiene, reduced neon...
A Purdue University-developed contraceptive vaccine reduces fertility in feral horses, deer, swine, and other animals, overcoming limitations of existing models. The vaccine, based on a male sperm protein, induces a long-lasting immune response and infertility in female mammals, with promising results for wildlife management.
The study found that the intranasal vaccine booster Clec9A OMNI induced significantly stronger neutralising antibody responses and robust T-cell responses in the lungs and nasal tissues, offering robust protection against SARS-CoV-2 Omicron infection. This breakthrough may address current shortcomings of COVID-19 mRNA vaccines, includi...
Researchers developed a universal vaccine formula that provides broad protection against respiratory viruses, bacteria and even allergens. The vaccine is delivered intranasally and works for a wide spectrum of respiratory threats, including SARS-CoV-2 and common hospital-acquired infections.
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
Researchers have identified a molecular trigger for rare blood clotting conditions after COVID19 adenovirus-based vaccines or natural adenovirus infections. The exact cause is now understood, allowing vaccine developers to adjust the adenovirus protein and prevent this extremely rare reaction.
A new HPV cancer vaccine developed by Northwestern University scientists has shown promising results in a preclinical model. The vaccine's carefully organized structure dramatically enhances the immune system's ability to attack tumors, shrinking them and extending animal survival.
The partnership aims to develop next-generation mRNA vaccines with enhanced stability and targeted delivery, providing broader protection against emerging pathogens. This collaboration combines Ethris' mRNA technology platforms with DZIF's vaccine research expertise to accelerate the development of variant-ready vaccines.
A team of researchers at Binghamton University is developing a new yeast-based solution for the production of better avian flu vaccines. The project aims to improve manufacturing, storage, and transportation efficiency compared to current options.